October 7, 2025
Trividia Health, Inc. has initiated a voluntary recall of a limited number of its TRUE METRIX® self-monitoring blood glucose meters after detecting potential defects in their LCD displays that could impair accurate reading. The recall was formally published by the U.S. Food and Drug Administration on October 7, 2025.
Scope & Lot: The recall affects 601 units from lot KD0746, manufactured on September 4, 2025, and distributed between September 8 and September 16, 2025.
Defect Description: The LCD displays in the affected meters may show partial or missing numerical segments, ghosting (fading segments), or incomplete characters. This can lead to misinterpretation of glucose values or delays in reading.
Safety Concern: For users with hypoglycemia (low blood sugar), a delayed or incorrect reading may lead to delayed treatment decisions, increasing risk.
Reported Harm: Trividia and the FDA state that no injuries have been reported to date in connection with this defect.
Check whether your meter is part of the recalled lot (KD0746). The lot number is printed on the packaging or side of the meter box.
Call the Trividia Health Customer Care Department at 1-888-835-2723 (Monday–Friday, 8 a.m.–8 p.m. EST) to verify if your meter is affected by serial number.
Alternatively, email trividia0925CC@trividiahealth.com or visit www.trividiahealth.com/productnotice for a lookup tool.
If your meter is affected, Trividia will assist you with instructions for return and replacement.
Healthcare Providers, Pharmacies, Distributors
• Inventory audit: check stock for units with lot KD0746.
• Quarantine affected units until they are returned.
• Notify patients, clinics, and customers about the recall if they may be using the affected meters.
• Meters from other lots not included in the recall may continue to be used.
• Users of recalled units should switch to an alternative validated meter until a replacement is provided.
At first glance, a glucose meter recall may seem peripheral to surgical device news. However, in a hospital or surgical center setting, glucose monitoring is integral to perioperative care, critical care, and diabetic patient management. Errors or delays in glucose readings can impact insulin dosing, patient safety, and postoperative outcomes.
For supply chain, procurement, and materials management teams, this recall underscores:
• The importance of lot-level traceability across all classes of devices, not just high-cost implants.
• A need for rapid reaction workflows when recall notices are issued, including cross-departmental coordination (pharmacy, endocrinology, nursing, hospital operations).
• The possibility that even “routine” or low-cost devices carry clinical risk and require the same vigilance as “major” devices.
Furthermore, this event aligns with broader regulatory trends emphasizing postmarket surveillance, device performance tracking, and the concept that quality must extend beyond manufacture into deployment.
This recall is being conducted in coordination with the FDA. The agency posted Trividia’s company announcement on its official “Recalls, Market Withdrawals & Safety Alerts” page.
